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ABSTRACT
Triple-negative breast cancer (TNBC) is the most lethal form of breast cancer. 
Lacking effective therapeutic options hinders treatment of TNBC. Here, we show that 
bepridil (BPD) and trifluoperazine (TFP), which are FDA-approved drugs for treatment 
of schizophrenia and angina respectively, inhibit Akt-pS473 phosphorylation and 
promote FOXO3 nuclear localization and activation in TNBC cells. BPD and TFP inhibit 
survival and proliferation in TNBC cells and suppress the growth of TNBC tumors, 
whereas silencing FOXO3 reduces the BPD- and TFP-mediated suppression of survival 
in TNBC cells. While BPD and TFP decrease the expression of oncogenic c-Myc, KLF5, 
and dopamine receptor DRD2 in TNBC cells, silencing FOXO3 diminishes BPD- and TFP-
mediated repression of the expression of these proteins in TNBC cells. Since c-Myc, 
KLF5, and DRD2 have been suggested to increase cancer stem cell-like populations 
in various tumors, reducing these proteins in response to BPD and TFP suggests a 
novel FOXO3-dependent mechanism underlying BPD- and TFP-induced apoptosis in 
TNBC cells.
INTRODUCTION
Breast cancer (BCa) is the most common cancer 
in women worldwide, with nearly 1.7 million new cases 
diagnosed and more than 520,000 related deaths in 2012 
[1]. Many patients with advanced BCa will eventually 
have a recurrence, often with the loss of chemo-sensitivity 
and a poor prognosis [2–4]. Triple-negative breast cancers 
(TNBCs) are defined by the absence of expression of 
estrogen and progesterone receptors and HER2 receptors, 
and they account for approximately 15% of all breast 
cancers [5, 6]. However, TNBC has a much higher rate of 
mortality than non-TNBC breast cancers because treatment 
of this aggressive form of cancer is limited to conventional 
chemotherapy [7]. Currently TNBCs still have no effective 
targeted therapy; thus, there is clearly an unmet medical 
need to find new effective targeted therapeutic drugs for 
this disease. Although recent clinical investigations of 
agents such as poly(ADP-ribose) polymerase (PARP) 
inhibitors or EGFR inhibitors have emerged, outcomes from 
recent clinical trials have been rather disappointing, with 
substantially less clinical effectiveness detected than was 
expected based on preclinical and early phase trials [8–10]. 
It is crucial to develop novel targeted therapeutic drugs.
FOXO3 is a key protein that controls the 
transcription of a number of genes crucial for regulating 
cell cycle control [11], DNA damage and stress responses 
[12–15], aging and longevity [12, 16], cellular apoptosis 
[12, 17–19], and suppression of cancer [20–23] in animal 
and human cells; gene knockout findings reveal FOXO3’s 
additional functions in tumor suppression [24] and the 
maintenance of the hematopoietic stem cell pool [25]. 
While multiple mechanisms have been shown to regulate 
FOXO3 activity, phosphorylation inhibits FOXO3 
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nuclear translocation that controls its regulation and 
function. In proliferating cancer cells, survival signals 
trigger PI3K to activate Akt which in turn phosphorylates 
and inhibits specific pro-apoptotic targets such as Bad, 
caspase-9, and FOXO3 [12, 17]. Consequently, loss of 
function of FOXO3 has been linked to tumorigenesis and 
poor patient survival in breast cancer [20, 22, 23] and 
other cancers such as lung cancer [26], prostate cancer 
[27], and ovarian cancer [28]. In the absence of survival 
signal stimulation, the Akt pathway is inactivated and 
its cellular targets such as FOXO3 can translocate to the 
nucleus and induce the expression of cell cycle regulators 
(e.g., p27Kip1) that lead to cell cycle arrest, or upregulate 
certain genes (e.g., Fas-ligand and Bim) that result in 
apoptosis depending on the physiological conditions 
and the cell types [11, 12, 17–19]. The nuclear exclusion 
and translocation of FOXO3 into the cytoplasm inhibits 
FOXO3-dependent transcription. These findings suggest 
that FOXO3 is a pivotal tumor suppressor, and the 
regulation of FOXO3 activation in cancer cells may be a 
promising approach for developing anticancer therapeutic 
drugs. The identification of novel small molecules that 
can promote the activity of FOXO3 in TNBC cells 
can provide leads for new TNBC therapeutics against 
malignant breast tumors in which the PI3K/Akt and/or 
IKK/NF-kB signaling pathways are aberrantly activated, 
and these molecules may also result in safe and effective 
targeted therapy of TNBC.
In this study, we develop a new breast cancer cell-
based enzymatic assay as the output to identify small-
molecule drugs that increase the activity of FOXO3 by 
screening a druggable library of known compounds 
that have been approved by the Food and Drug 
Administration (FDA) because it has been suggested that 
the most fruitful basis for the discovery of a new drug is to 
seek new uses for old drugs [29]. Here we show anticancer 
properties and the preclinical therapeutic effects of two 
representative FDA-approved small-molecule drugs, 
bepridil (BPD) and trifluoperazine (TFP), which have been 
used clinically for treatment of schizophrenia and angina, 
respectively [30, 31]. 
Both TFP and BPD show potent cytotoxic activity 
in TNBC cells in culture and exhibit antitumor activity 
in TNBC in vivo models. Activation of FOXO3 tumor 
suppressor by TFP or BPD is a significant distinction 
from traditional antipsychotic inhibitors and the resultant 
downregulation of oncogenic survival factors, c-Myc 
[32] and Kruppel-like factor 5 (KLF5) [33], in TNBC 
is an interesting anticancer mechanism. Unexpectedly, 
we uncover that both TFP and BPD display suppression 
of the expression of the dopamine receptor D2 (DRD2), 
which has been suggested as a key receptor for selective-
targeting cancer stem cells (CSC) [34], in a FOXO3-
dependent manner. This novel finding may broaden the 
potential therapeutic applications beyond TNBC tumors, 
which are enriched with CSC characteristics. 
RESULTS
Identification and validation of FDA-approved 
FOXO3-activating small-molecule drugs
To identify small molecules that can induce 
the activity of FOXO3 in BCa cells, we developed a 
new BCa cell-based enzymatic (ELISA) assay as the 
output to identify small molecules that can significantly 
inhibit the phosphorylation of Serine (S)-318/321 of 
FOXO3 (FOXO3-pS318/321), which is primarily 
localized in the cytoplasm of cells. Decreasing the level 
of phospho-FOXO3 leads to an increase of FOXO3 
nuclear localization and its activity in BCa cells. The 
screening method is depicted in Figure 1A. To expedite 
the future clinical trials for novel lead small-molecule 
compounds, we screened 640 small-molecule drugs from 
a commercially available FDA-approved small-molecule 
library with this ELISA assay using a specific antibody 
against FOXO3-pS318/321. We used LY294002 and 
Wortmanin (the Akt inhibitors) as positive (inhibition) 
controls and DMSO as negative control. A representative 
screening result of our primary screen with these drugs 
(20 µg/ml) in MCF7 cells is shown in Figure 1B. After 
the primary screen, we initially selected 19 candidate 
small-molecule compounds for further confirmation by 
carrying out the secondary screen with two different BCa 
cell lines (MDA-MB-231 and MCF7). In total, twelve 
candidate compounds were confirmed, which showed 
a decrease of the level of FOXO3-pS318/321 around 
50% in each cell line as compared with negative control 
(DMSO) (Figure 1C). Among them, seven top-ranked 
compounds were selected, which showed a decrease 
of the level of FOXO3-pS318/321 greater than 50% in 
both BCa cell lines as compared with negative control, 
after our secondary screens. The structures, original 
clinical applications, and their identification numbers 
corresponding to the results in Figure 1C are exhibited in 
Figure 1D. While these 7 drugs have no common chemical 
structure, two of them (BPD and TFP) have been shown 
to target the same protein, calmodulin, and both of them 
have been clinically applied to the same disorder as 
antipsychotic drugs [30, 31]. Thus, we focused on these 
two drugs for further studies. 
TFP and BPD induce nuclear localization and 
activating of FOXO3 in TNBC cells
To determine whether the treatment of TFP and 
BPD can increase the expression level of FOXO3 and its 
transcriptional activity, we treated TNBC MDA-MB-231 
and BT549 cells with various doses of TFP or BPD for 
24 hours and performed immunoblotting experiments 
with total lysates of these drug-treated cells. Our data 
show that TFP or BPD treatment leads to significant 
upregulation of the expression of FOXO3 and p27Kip1 
Oncotarget42112www.impactjournals.com/oncotarget
Figure 1: Primary and secondary screens of small-molecule drugs using a cell-based ELISA assay. (A) Schematic diagram 
depicts the cell-based ELISA assay used for our drug screening. (B) One representative outcome of our cell-based ELISA assay is shown. 
In principle, breast cancer cells (e.g., MDA-MB-231) were seeded in a 96-well tissue culture plate. The cells were fixed after various 
treatments such as the small molecule library. After blocking, anti-phospho-FOXO3 specific antibody is incubated into the wells. The wells 
were washed, followed by the addition of HRP-conjugated anti-IgG secondary antibody. The wells were washed again, a substrate solution 
is added to the wells and color develops in proportion to the amount of protein. The Stop Solution changed the color from blue to yellow, 
and the intensity of the color was measured at 450 nm. (C) Secondary screening results obtained from MDA-MB-231 and MCF7 cells are 
shown. WT, Wortmanin. (D) The structures and original clinical applications of seven candidate compounds are shown.
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and SOD2, transcriptional targets of FOXO3, in both 
cell lines (Supplementary Figure S1). In addition, TFP or 
BPD treatment significantly inhibits the phosphorylation 
level of Akt-Serine 473 (Akt-pS473), a key kinase that 
phosphorylates FOXO3, in both cell lines in a dose-
dependent manner. These results suggest that TFP or BPD 
treatment can inhibit Akt activity, resulting in increasing 
FOXO3 transcriptional activity. 
To determine whether TFP or BPD treatment can 
increase the nuclear translocation of FOXO3, we treated 
MDA-MB-231 and BT549 cells with various doses of 
TFP or BPD for 24 hours and performed immunoblotting 
experiments with nuclear/cytoplasmic extracts from 
these cells. Our data indicate that TFP or BPD treatment 
increases the level of nuclear FOXO3 and the expression 
of p27Kip1 in these cells in a dose-dependent manner 
(Figure 2A–2B; Supplementary Figure S2) and in a time-
dependent manner (Supplementary Figures S3 and S4). 
Meanwhile, these results are associated with a decrease 
or no change of FOXO3 level in the cytoplasm of these 
cells. We also treated BT549 cells with TFP or BPD or 
control (DMSO) for 24 hours and analyzed the subcellular 
localization of FOXO3 as well as the phosphorylation 
of S-15 of p53 (p53-pS15), a hallmark of DNA damage 
[35], in these cells using immuno-fluorescence analysis. 
Our results showed that TFP or BPD promoted nuclear 
localization of FOXO3 (i.e., activation of FOXO3) and 
induced phosphorylation of p53-pS15 in BT549 cells 
(Figure 2C), suggesting that TFP and BPD may induce 
DNA damage and activate FOXO3 in TNBC cells.
BPD and TFP suppress cell survival and promote 
cellular apoptosis in TNBC cells
To determine whether BPD and TFP treatments 
suppress cell survival, we treated MDA-MB-231 
and BT549 cells with various doses of BPD or TFP 
or DMSO (control) for 72 hours, and performed cell 
survival assays by the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assays. We found 
that BPD and TFP treatments significantly suppressed 
survival in these cells (Figure 3). To examine whether 
BPD and TFP treatments induce apoptosis, we treated 
MDA-MB-231 or BT549 cells with BPD or TFP and 
analyzed apoptosis by standard flow cytometry analysis 
with Annexin V staining, an indicator of apoptosis 
[36]. We showed that BPD and TFP treatments induced 
significant Annexin V-positive cell populations in a drug 
dose-dependent manner (Figure 4A–4B; Supplementary 
Figure S5). Moreover, we treated MDA-MB-231 or BT549 
cells with various doses of TFP or BPD and analyzed 
apoptosis by terminal deoxynucleotidyl transferase 
dUTP nick end labeling (TUNEL) apoptosis assays or 
immunoblotting analysis of poly-ADP-ribose polymerase 
(PARP) degradation, an indicator of apoptosis [37], assays 
or DNA fragmentation assays. Our data showed that BPD 
and TFP treatments induced significant TUNEL-positive 
cells, PARP-1 degradation, and an increase in the amount 
of DNA fragmentation ~24 hours post drug treatments, 
respectively (Figure 4B–4F; Supplementary Figure S6). 
These results suggest that BPD and TFP may suppress cell 
survival and promote apoptosis in TNBC cells.
BPD and TFP suppress the growth of TNBC 
tumors in vivo
To determine if treatment with BPD and TFP can 
suppress tumorigenesis or tumor growth in TNBC cells 
in vivo, we injected MDA-MB-231 TNBC cells into 
the flanks of female athymic nude mice. When palpable 
solid tumors were detected, the tumor-bearing mice were 
given an intravenous injection (0.1 ml) of BPD or TFP 
[10 mg/kg-body weight/mouse] or the vehicle (DMSO, 
negative control) three times per week at even intervals 
for 5 weeks. The tumor volumes were measured twice per 
week after the treatment. Our results show that BPD or 
TFP significantly suppressed MDA-MB-231 TNBC tumor 
growth in the mouse model (Figure 5).
Silencing FOXO3 potently decreases the TFP- or 
BPD-mediated suppression of cell survival in 
TNBC cells   
Since it is known that FOXO3 can regulate cell 
survival and proliferation (cycle control) [11] and that 
activation of FOXO3 can promote cellular apoptosis 
[12, 17–19], we sought to determine whether FOXO3 
is necessary for regulating TFP- or BPD-mediated 
inhibition of cell survival and proliferation in TNBC cells. 
We silenced endogenous FOXO3 in BT549 and MDA-
MB-231 cells by transfecting these cells with FOXO3-
siRNA or Control-siRNA (Figure 6A, 6C). Then, we 
treated these FOXO3-knockdown cells with TFP or BPD 
or DMSO (negative control) to compare the effects of 
these drugs on the rate of cell survival and proliferation 
by using the colony formation assay. While TFP or BPD 
treatment significantly suppressed the colony-forming 
ability of BT549 and MDA-MB-231 cells, silencing 
FOXO3 potently diminished the TFP- or BPD-mediated 
suppression of cell survival in these cells (Figure 6B, 6D). 
These results suggest that FOXO3 is essential for TFP and 
BPD-mediated suppression of cell survival of TNBC cells.
TFP and BPD significantly reduce the expression 
of oncogenic c-Myc, KLF5, and DRD2 in TNBC 
cells in a FOXO3-dependent manner
An important question in determining the 
mechanism for suppressing cell survival is how TFP 
and BPD contribute to the observed suppression of cell 
survival or growth in TNBC cells. Because it has been 
suggested that several cancer-promoting genes, such 
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Figure 2: TFP or BPD treatment significantly promotes nuclear translocation and activation of endogenous FOXO3 in 
TNBC cells. (A–B) MDA-MB-231 cells were treated with a dose response of TFP (A) or BPD (B) or dimethylsulfoxide (DMSO) control 
(denoted as 0 mM) for 24 hours, harvested, and fractionated for preparing cytoplasmic (Cyt.) and nuclear (Nuc.) extracts. Equal amount 
of each fraction was analyzed by immunoblotting (IB) analysis with specific antibodies as indicated. β-actin and PARP1 represent the 
fractionation and loading controls of the Cyt. and the Nuc. fractions, respectively. All these results shown above represented 3 independent 
experiments. (C–D) BT549 cells were treated with control (DMSO) or TFP (5 mM) or BPD (5 mM) for 24 hours. The treated cells were 
fixed and the subcellular localizations of endogenous FOXO3 and p53-pS15, a DNA damage marker, were detected using antibodies 
against FOXO3 and p53-pS15 and followed by an Alexa Fluor 594 (red)- or Alexa Fluor 488(green)-conjugated secondary antibody, and 
fluorescence microscopy. DAPI was used to show the nuclei, and co-localization of FOXO3 with p53-pS15 was shown as the merged 
images (orange or yellow color).
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Figure 3: The cytotoxic effect of TFP and BPD on human TNBC cells. The dose effects of TFP or BPD on cell viability of 
MDA-MB-231 (A or C) and BT549 (B or D) cells were determined. Cells were cultured in a 96-well plate (2,000 cells/well), treated 
with various doses of TFP or BPD as indicated, and incubated for 72 hours. The cell viability was determined by the MTT assay and the 
relative cell survival rate percentage was calculated by dividing the optical density of each drug treatment by that of the control (DMSO) 
treatment. Each data point represents the mean value from 3 independent experiments, with at least three replicates. The error bars represent 
standard deviation by paired t-test. The significant P-values between the treatment group versus the control group are indicated (*P < 0.05, 
**P < 0.01).
as Akt [38], c-Myc [32], KLF5 [33], and DRD2 [34] 
are involved in cell survival or proliferation in BCa 
cells, we sought to compare the status of these genes in 
human TNBC tumors versus non-TNBC tumors. Thus, 
we analyzed the gene amplification and mRNA copy 
number gain (amplification/gain) data available from The 
Cancer Genome Atlas (TCGA) datasets using cBioPortal 
[39, 40]. As shown in Figure 7A and 7B, the Akt2 gene’s 
amplification/gain alteration in 123 TNBC samples 
(21%) is about 2-fold higher than that in 104 non-TNBC 
samples (11%). The Akt3 and MYC genes’ amplification/ 
gain alterations are high (60%–71%) in both TNBC and 
non-TNBC samples, while the Akt1 gene’s amplification/
gain alteration is low (6% and 9% in TNBC and non-
TNBC samples, respectively) (not shown). Notably, 
while the KLF5 gene’s amplification/gain alteration in 
TNBC samples (12%) is 4-fold higher than that in non-
TNBC samples (3%), the DRD2 gene’s amplification/gain 
alteration in TNBC samples (11%) is 11-fold higher than 
that in non-TNBC samples (1%). 
To confirm that TFP or BPD treatment leads to 
significant downregulation of the expression of key 
oncogenic proteins in TNBC cells, we performed 
immunoblotting experiments with nuclear/cytoplasmic 
extracts from the drug-treated cells as described above. 
Our data demonstrate that TFP or BPD treatment 
significantly suppressed of the expression of oncogenic 
c-Myc, KLF5, and DRD2 in BT549 cells (Figure 7C–7D). 
As controls, our data also show that TFP or BPD treatment 
potently increased the levels of FOXO3, p27Kip1, 
g-H2AX, and p53-pS15 in BT549 cells, while TFP or 
BPD treatment decreased the phosphorylation level of 
Akt-pS473 as described above. 
To confirm that FOXO3 is essential for regulating 
the drug-mediated suppression of the expression of these 
oncogenic proteins, we transfected BT549 cells with 
FOXO3-siRNA or Control-siRNA (negative control) 
and performed immunoblotting analysis with nuclear/
cytoplasmic extracts from the drug-treated cells as 
described above. Our results show that the expression 
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Figure 4: BPD and TFP promote cellular apoptosis in TNBC cells. (A–B) MDA-MB-231 cells were treated with TFP or BPD 
or DMSO (negative control) or camptothecin (CPT) (positive control) for 48 hours, harvested, and were subjected to Annexin V and 
propidium iodide staining for determining apoptosis. (B) An average (%) of Annexin V-positive cells (apoptotic) cells was determined 
and shown in the diagram. Each data point represents the mean value from 3 independent experiments. The error bars represent standard 
deviation (SD). P values between the test-group treated with drugs versus the control-group treated with DMSO are shown. (C–E) MDA-
MB-231 cells were treated with TFP or BPD or DMSO for 48 hours, and the cells were fixed on the slides for determining apoptosis by 
TUNEL assay. Nuclei were stained with DAPI (color-inverted to red), and merged images (yellow) were considered as apoptotic cells. 
Scale bar: 20 mm. (D, E) An average (%) of apoptotic (TUNEL-positive) cells was determined and shown in the diagram. The samples 
include three biological replicates. The error bars represent SD, and P values are shown. (F–G) MDA-MB-231 (F) or BT549 (G) cells were 
treated with TFP or BPD or DMSO for 48 hours. Total lysates of cells were analyzed by Immunoblotting analysis with specific antibodies 
against full-length PARP1 protein or cleaved PARP1 fragment (89 kDa) as indicated. β-actin represents the loading controls.
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Figure 5: BPD and TFP suppress the growth of TNBC tumors in the mouse tumor model. (A–B) MDA-MB-231 cells were 
injected into female nude mice (n = 3/group). The tumor-bearing mice were given an i.v. injection of (A) BPD (10 mg/kg) or the vehicle 
control (DMSO), and (B) TFP (10 mg/kg) or DMSO twice per week. The tumor volumes [(L × W2)/2] were measured. The results are 
graphed as mean ± SEM numbers of tumor volumes. Significant P values are shown. *P < 0.05.
of c-Myc, KLF5, and DRD2 in BT549-Control-siRNA 
cells was downregulated significantly after TFP or BPD 
treatment, whereas the drug-mediated downregulation 
of the expression of c-Myc, KLF5, and DRD2 was 
diminished in BT549-FOXO3-siRNA cells (Figure 8A). 
Similarly, the drug-mediated increase of the levels of 
FOXO3 and g-H2AX was diminished in BT549-FOXO3-
siRNA cells, while the levels of FOXO3 and g-H2AX in 
BT549-Control-siRNA cells were increased significantly 
after the drug treatment (Figure 8A). Taken together, these 
results suggest that FOXO3 may be essential for TFP- or 
BPD-mediated repression of the expression of c-Myc, 
KLF5, and DRD2 in TNBC cells.
DISCUSSION 
Here, we provide evidence that pharmacological 
activation of FOXO3 by small-molecule drugs (TFP or 
BPD) potently suppresses cell survival and proliferation 
in TNBC cells in vitro and in TNBC tumors in vivo. 
TNBC has been clinically proven to be associated with 
a shorter median time to relapse and death and does not 
respond to endocrine therapy or other available targeted 
agents at present. Increased aggressiveness of this tumor, 
as well as resistance to standard drug therapies, may be 
linked to the presence of CSC populations within TNBC 
tumors. However, if anticancer therapies can eliminate 
differentiated cancer cells but cannot overcome CSC 
populations in TNBC tumors, a small population of tumor-
initiating CSC may remain untouched and cause relapse in 
the future. Thus, it is important to identify new therapeutic 
drugs that can specifically target CSC populations in 
tumors. Our results show that both TFP and BPD suppress 
the expression of oncogenic c-Myc, KLF5, and DRD2 
proteins, and silencing FOXO3 significantly diminishes 
TFP- or BPD-mediated repression of the expression of 
these proteins in TNBC cells. In addition to upregulation 
of p27Kip1, activation of FOXO3 upregulates 
pro-apoptotic Bax and Bim proteins [17, 19, 41]. Thus, 
we have proposed a schematic representation of the 
FOXO3-dependent promotion of apoptosis in TNBC cells 
in response to the treatment of BPD or TFP (Figure 8B). 
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Figure 6: TFP and BPD suppress the colony-forming ability of TNBC cells in a FOXO3-dependent manner. (A–B) (A) 
BT549 cells were transfected with control-siRNA or FOXO3-siRNA for 48 h. The indicated proteins were detected by immunoblotting with 
specific antibodies (Abs) against FOXO3 and GAPDH (loading control). (B) The transfected cells were treated with TFP, BPD or DMSO 
(negative control) for 14 days and stained with crystal violet solution. Top (upper panels): the representative pictures of the assays are 
shown. Bottom (lower panels): the numbers of colonies in the drug (TFP or BPD)-treated plates were compared with those of the DMSO-
treated plates. The results are graphed as mean ± SEM numbers of cell colonies. The number of biological replicates is three. *P < 0.001 
(drug vs DMSO). (C–D) (C) MDA-MB-231 cells were transfected with control-siRNA or FOXO3-siRNA, and the indicated proteins were 
determined as described above. (D) The transfected cells were treated with TFP, BPD or DMSO (negative control) for 14 days, stained, and 
the data are presented as described above.
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Figure 7: The aberrant expression of oncogenic survival proteins in TNBC tumors and the effect of TFP or BPD 
on these proteins in TNBC cells. (A–B) Oncoprint analysis data of Akt2, Akt3, c-Myc (MYC), Kruppel-like factor 5 (KLF5), and 
dopamine receptor D2 (DRD2) in TNBC patient samples are displayed. Data from the TCGA dataset containing molecular subtyping data 
of 123 TNBC subtype (A) and 104 non-TNBC subtype (B) were extracted and used to generate an oncoprint plot using the cBioPortal 
[39, 40]. Gene amplification (red bars) and mRNA copy number gain (pink bars) are shown. (C–D) BT549 cells were treated with a dose 
response of TFP (C) or BPD (D) or DMSO control (denoted as 0 mM) for 24 hours, harvested, and fractionated for preparing cytoplasmic 
(Cyt.) and nuclear (Nuc.) extracts. Equal amount of each fraction was analyzed by immunoblotting (IB) analysis with specific antibodies 
as indicated. While a-Tubulin and GAPDH represent the loading controls of the Cyt. extract, Lamin A/C displays the loading control of 
the Nuc. Extract.
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Figure 8: TFP and BPD significantly reduce the expression of oncogenic c-Myc, KLF5, and DRD2 in TNBC cells in a 
FOXO3-dependent manner. (A) BT549 cells were transfected with control-siRNA or FOXO3-siRNA for 24 hours, transfected cells 
were treated with TFP, BPD or DMSO (control) for 48 hours, harvested, and fractionated for preparing cytoplasmic and nuclear extracts. 
Equal amount of each fraction was analyzed by immunoblotting (IB) analysis with the specific antibodies as indicated. Proteins β-Actin and 
PARP1 represent the fractionation and loading controls of the cytosolic and nuclear fractions, respectively. (B) A diagram represents the 
model for the FOXO3-dependent anticancer function of BPD and TFP. A schematic shows that BPD and TFP inhibit phosphor-Akt (pAkt) 
and lead to FOXO3 translocation from the cytoplasm into the nucleus, where FOXO3 can upregulate the expression of p27Kip1, Bax, and 
Bim proapoptotic proteins [17, 19, 41]. Moreover, BPD and TFP downregulate of the expression of c-Myc, KLF5 and DRD2 oncogenic 
survival proteins in a FOXO3-dependent manner. As a result of this FOXO3-mediated apoptotic pathway, BPD and TFP promote TNBC 
cell apoptosis.
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It has been shown that Akt is aberrantly expressed 
or constitutively activated in several cancers including 
BCa [38]. Based on the relative phosphorylation status of 
FOXO3 (Ser318/321) by Akt in cells treated with drugs, 
we have developed a new cell-based screening system 
for selecting small-molecule drugs that promote FOXO3 
nuclear localization in BCa cells. Through this novel 
screening system, we have identified and validated several 
candidate drugs from an FDA-approved small-molecule 
library. A key advantage of repurposing FDA-approved 
drugs is that the toxicity profiles, pharmacokinetic, and 
pharmacodynamic studies of these drugs have already 
been approved by the FDA; thus, saving cost and time 
for new drug development [29]. In addition, based on the 
known activities of existing drugs, the mechanisms of 
new actions of these drugs tend to be more predictable 
and successful than those made of entirely unknown 
compounds. For examples, while aspirin has been 
previously used as an analgesic to relieve pain, it has 
been recently shown to exert anti-platelet activity and is 
rapidly being repurposed for preventing cardiovascular 
diseases [42]. Before thalidomide was found to cause birth 
defects, it was used to treat morning sickness in pregnant 
women. When it was found to cause birth defects, it was 
taken off the market. Later, through drug repurposing, 
it became available again as a treatment for multiple 
myeloma and leprosy. Milnacipran was initially used as 
an antidepressant drug but it became one of three modern 
drugs for treating fibromyalgia. Finally, thioridazine, an 
anti-psychotic drug, was repurposed to selectively inhibit 
the development of acute myeloid leukemia derived from 
their CSC through antagonizing DRD2 [34]. 
We focused on two drugs (TFP and BPD) based 
on their same target and similar clinical applications. 
In agreement with our findings, TFP has been shown 
to induce apoptosis in A549 lung cancer cell line that 
is associated with downregulation of anti-apoptotic 
Bcl-2 protein and upregulation of pro-apoptotic Bax 
protein [43]. BPD has recently been shown to stimulate 
the tumor necrosis factor-related apoptosis-inducing 
ligand (TRAIL)-mediated apoptosis in U251MG 
glioblastoma cell line via upregulation of the expression 
of death receptor 5 (DR5) [44]. Interestingly, FOXO3 
can upregulate the expression of TRAIL in prostate 
cancer cells [45], and FOXO3 may be essential for the 
expression of DR5 in colon and live cancer cells [46, 47]. 
However, the roles and mechanisms of TFP and BPD in 
suppressing TNBC cell survival and tumor development 
are unknown and have not yet been explored. TFP and 
BPD are known to be calmodulin antagonists, which have 
been used clinically for treating psychotic disorders such 
as schizophrenia and cardiac arrhythmia. Our current data 
indicate a successful case of repurposing TFP and BPD for 
treating TNBC. More importantly, we show that TFP and 
BPD treatments promote suppression of the expression 
of specific oncogenes (c-Myc, KLF5, and DRD2), which 
are suggested to increase CSC-like populations in various 
tumors [34, 48–50]. Also, our data suggest an essential 
role of FOXO3 in TFP/BPD-induced downregulation of 
these CSC-related oncogenic proteins, which is consistent 
with our recent finding suggesting that FOXO3 may 
be necessary for certain drug-mediated suppression of 
the expression of markers (such as c-Myc and CD44) 
exhibiting CSC characteristics in TNBC cells [51]. 
Moreover, TFP has a very similar chemical structure to 
thioridazine, a CSC targeting drug that selectively inhibits 
CSC [36], and both drugs exert similar pharmacological 
effects when clinically treating psychotic disorders. 
Collectively, our novel findings suggest that TFP and 
BPD may become potential therapeutic drugs for TNBC, 
although further investigation of this therapeutic concept 
of targeting CSC in TNBC tumors with TFP and BPD (or 
their analogs) is necessary to establish novel therapeutic 
interventions in order to conquer malignant TNBC in the 
future.
MATERIALS AND METHODS
Cell culture, cell lines, shRNA and siRNA 
transfection 
BT549 (human breast epithelial ductal carcinoma), 
MDA-MB-231 (human breast invasive ductal carcinoma), 
and MCF7 (human breast adenocarcinoma) cell lines were 
obtained from the American Type Culture Collection, and 
grown in DMEM/F12 supplemented with L-glutamine 
(3%), penicilline/streptomycin (1%) and 10% fetal bovine 
serum at 37oC in a humidified CO2 incubator (5% CO2). 
Specific siRNA against FOXO3 (sc-37887) and control-
siRNA (sc-44231) were obtained from Santa Cruz 
Biotechnology (SCBT) (Santa Cruz, CA). For transfection 
with siRNA, cells were transfected with specific siRNA 
or control siRNA as indicated by using DharmaFECT 1 
transfection reagent (Thermo Scientific, Rockford, IL) 
according to the manufacturer’s protocol. 
Antibodies and reagents
TFP, dimethylsulfoxide (DMSO), 3-(4,5- 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT), and 3,3′,5,5′-Tetramethylbenzidine (TMB) were 
purchased from Sigma (St. Louis, MO). Propidium 
iodide (PI) was obtained from Fisher Scientific. BDP 
and antibodies specific to FOXO3 (FKHRL1) N-16 
(1:500 dilution) and H-144 (1:1000 dilution), p53-pS15 
(1:1000 dilution), c-Myc (1:1000 dilution), a-Tubulin 
(1:2000 dilution), PARP1 (1:1000 dilution), SOD2 
(1:2000 dilution), and Lamin A/C (1:1000 dilution) 
were purchased from SCBT. Antibody against phospho-
H2AX Serine-139 (1:1000 dilution) was obtained from 
Millipore (Billerica, MA). Specific antibodies against 
phospho-FOXO3-S318/321 (#9465, 1:250 dilution), 
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Akt-pS473 (1:1000 dilution), Akt (total, 1:1000 dilution), 
and p27Kip1 (1:1000 dilution) were purchased from Cell 
Signaling Technology (Danvers, MA). Antibodies against 
FOXO3 (2071-1 and 3280-1) (1:1000 dilution) were 
obtained from Epitomics (Burlingame, CA). Antibody 
against β-Actin (1:3000 dilution) was purchased from 
Sigma. Antibody against GAPDH (1:1000 dilution), Alexa 
488- and Alexa 594-conjugated secondary antibodies 
were obtained from Thermo-Fisher Scientific (Waltham, 
MA). Goat anti-mouse IgG and goat anti-rabbit IgG 
horseradish peroxidase-conjugated secondary antibodies 
were purchased from Jackson ImmunoResearch (West 
Grove, PA).
Cell-based ELISA assay
Cells (2 × 104/well in 100 µl medium) were seeded 
into 96-well black microplates and incubated at 37oC for 24 
hours in a CO2 incubator. Cells in each well were treated 
separately with DMSO (negative control), LY294002 
or Wortmannin (negative controls), and small-molecule 
compounds (20 µg/ml final conc.) from the FDA-Approved 
Drug Library (from Enzo Life Sciences International, Inc) 
(totally 640 drugs, 80 drugs per 96-well plate) at 37°C and 
5% CO2 for 24 hours. Then, cells were fixed and quenched 
by adding 100 µl of 4% formaldehyde [in phosphate-
buffered saline (PBS)] and 100 µl of 0.6% H2O2 (in PBS), 
respectively. To determine the level of the phosphorylated-
FOXO3-S318/321 in these cells, ELISA was performed 
by treating cells with 100 µl of the blocking buffer [5% 
bovine serum albumin (BSA) in Tris-buffered saline, 0.1% 
Tween-20 (TBST)] for I hour. After washing, cells were 
treated with 100 µl of primary antibody against phospho-
FOXO3-S318/321 (1:250 dilution in TBST containing 
2% BSA) at 4°C for overnight. After washing, cells were 
treated with 100 µl of the anti-rabbit IgG horseradish 
peroxidase-conjugated secondary antibody (1:1000 dilution 
in TBST containing 2% BSA) at room temperature for 2 
hours. After washing, cells were treated with 100 µl of 
peroxidase substrate (TMB) for 15 minutes, followed by 
adding 50 µl of ELISA stop solution (2N H2SO4). The 
optical density of each well was measured by reading the 
microplate using a microplate reader at 450 nm.
Immunofluorescence analysis 
Experiments were essentially performed as 
described [41, 51]. Briefly, BT549 cells were treated 
with TFP (5 mM) or BPD (5 mM) or vehicle (DMSO) for 
24 hours, fixed, and permeabilized. After blocking with 
BSA, cells were incubated with a primary antibody against 
FOXO3 (1:50 dilution) or p53-pS15 (1:100 dilution), 
followed by Alexa 594 (red)-conjugated anti-rabbit (1:200 
dilution) or Alexa 488 (green)-conjugated anti-mouse 
(1:200 dilution) secondary antibody, respectively. After 
counterstaining with DAPI, fluorescence images were 
captured with a confocal microscope. The percentage 
of nuclear FOXO3-positive cells was quantitated by 
analyzing ~100 cells images randomly captured by 
confocal microscopy with the Image J software (v.1.49).
Cytoplasmic and nuclear protein fractionation
Experiments were performed as described [19, 41]. 
Briefly, TNBC cells from various treatment conditions 
were trypsinized, centrifuged, washed, re-suspended in 
a cytoplasmic fractional buffer and incubated at 4°C for 
30 min. The cell suspension was centrifuged at 10,000 rpm 
for 30 min at 4°C and the supernatant was collected for 
cytoplasmic fraction. The nuclear pellet was washed twice 
with the washing buffer. The remaining pellet was re-
suspended with a nuclear fractional buffer and incubated 
at 4°C for 30 min. The nuclear suspension was centrifuged 
at 13,000 rpm for 30 min at 4°C, the supernatant was 
collected for nuclear fraction. Protein in each fraction was 
quantified as described [19, 41].
Immunoblotting analysis
For immunoblotting (Western blotting) analysis, 
equal amount (20–50 mg) of each protein sample was 
subjected to SDS-PAGE (8%–12%) and transferred 
onto nitrocellulose membranes as described [19, 41, 51]. 
Briefly, membranes were blocked in 3% BSA in 
TBST buffer and incubated for 1 hour with a primary 
antibody. After three washes with TBST, membranes 
were incubated for 1 hour with horseradish peroxidase-
conjugated secondary antibodies (1:3000 or 1:5000 
dilution). The immunoblots were visualized by enhanced 
chemiluminescence as described [19, 41, 51].
MTT assays 
TNBC cells (1 × 103/well) were seeded into 
96-well plates and incubated at 37°C in a CO2 incubator 
(5% CO2) overnight. TNBC cells were treated with 
DMSO (control) and various doses of TFP or BPD as 
indicated for 72 hours, followed by the addition of 20 µl 
of MTT solution (5 mg/ml in phosphate buffer). After 
incubation for 2 hours, the solution in each well was 
removed, and then the blue crystalline precipitate in each 
well was dissolved in DMSO (200 µl/well). The visible 
absorbance at 545 nm of each well was quantified using 
a microplate reader.
Annexin V staining fluorescence-activated cell 
sorting (FACS) analysis
The percentage of cells that are undergoing 
apoptosis was determined by using the FITC Annexin 
V Apoptosis Detection Kit I (BD PharMingen) with 
propiodium iodide according to the manufacturer’s 
instructions. After treatment with various doses of TFP 
or BPD or DMSO (negative control) or camptothecin 
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(positive control) for 48 hours, cells were washed in PBS, 
trypsinized, and resuspended in binding buffer [10 mM 
Hepes/NaOH (pH 7.4), 140 mM NaCl, 2.5 mM CaCl2] at 
a density of 1 × 106 cells/ml.
Afterwards, the cells were aliquoted into 5 ml 
culture tubes (1 × 105 cells/tube) and incubated in binding 
buffer containing 5 μl of FITC Annexin V and 5 μl of PI 
for 15 min at 25°C in the dark. Cells were analyzed by 
using a FACScan or FACSCalibur (BD Biosciences) at 
the Institutional shared FACS Facility and the data were 
analyzed by FlowJo or FCS 5 Express (De Novo Software, 
CA). Ten thousand events were collected in each run. Each 
data point represents the mean value from 3 independent 
experiments. The error bars represent standard deviation 
(SD), and the statistical test is the unpaired t-test.
Terminal deoxynucleotidyl transferase dUTP 
nick-end labeling (TUNEL) 
Experiments were performed as described [41]. 
Briefly, MDA-MB-231 cells were grown on glass 
coverslips. After treatment with various doses of TFP or 
BPD or DMSO (control) for 48 hours, cells were fixed 
with 4% paraformaldehyde solution and permeabilized 
with Triton X-100 (0.2%). For TUNEL assay, cellular 
apoptosis assay was determined by enzymatic labeling of 
DNA strand breaks with a TUNEL assay kit (the DeadEnd 
Fluorometric TUNEL System, Promega) according to 
the manufacturer’s instructions. Nuclei were stained 
with DAPI (color was inverted to red). Merged images 
(yellow) were considered as apoptotic cells and counted 
under a confocal laser-scanning microscope (Leica SP2 
AOBS). The samples include three biological replicates, 
the error bars represent SD, and the statistical test is the 
paired t-test.
DNA fragmentation assay 
TNBC cells (2 × 107 per sample) were trypsinized, 
lysed in the lysis buffer (10 mM Tris-HCl, 10 mM EDTA, 
0.1% Triton-X 100, 0.1% SDS and pH 7.5) and incubated 
on ice for 30 min. The lysates were digested with RNase 
I followed by digestion with proteinase K. The DNA was 
extracted by phenol-chloroform (1:1, v/v), precipitated 
with 2 volumes of EtOH plus 10% NaAc (3 M, pH 5.2) 
and then dissolved in distilled water. Equal amounts of 
the extracted DNA (2 μg/lane) and size markers (1-kb 
ladder) were subjected to electrophoresis on 2% agarose 
gels, which were stained with ethidium bromide and 
photographed.
Colony formation assay
TNBC cells (0.5 × 103) were seeded into 6 cm dishes 
and incubated at 37°C in a humidified incubator containing 
5% CO2 for 18 hours. After incubation, cells were treated 
with DMSO as control vehicle and TFP (5 μM) or BPD 
(5 μM) for 14 days. Then, the colonies were washed 
twice with PBS, fixed with 3.7% Paraformaldehyde, and 
stained with 1% crystal violet solution in distilled water. 
Experiments were performed three times. 
Animal studies 
To determine the antitumor effect of TFP and 
BPD in vivo, female athymic (nu/nu) nude mice were 
purchased from Charles River Laboratories, Inc. 
(Wilmington, MA) and maintained aseptically in an 
athymic animal room. For tumor-cell implantation, 
MDA-MB-231 cells (in log-phase growth) were 
harvested, washed with PBS, and re-suspended in PBS. 
Then cells (5 × 106 in 0.1 ml PBS with 30% ECM gel) 
were injected subcutaneously into the flank of each 
mouse as described previously [51, 52]. When palpable 
solid tumors were detected (approx. 100 mm3), each 
group of mice was given an intravenous (i.v.) injection 
(0.1 ml) of BPD or TFP (10 mg/kg-body weight/mouse) 
three times per week at even intervals for five weeks. 
The vehicle (DMSO) was used as a negative control 
group. The tumor sizes were measured twice per week 
with a Vernier caliper. Data are presented as means and 
standard deviations (SD) of four mice in each group. 
Mice were weighed twice per week as a measure of 
overall systemic toxicity. All procedures were performed 
in compliance with the guidelines and regulations of the 
Institutional Animal Care and Use Committee (IACUC). 
The IACUC has approved the experiments listed in the 
Protocol number 21557 (Stanford’s Animal Welfare 
Assurance Number: A3213-01). 
Statistical analysis
All data are expressed as means and SD from at 
least three determinations. The statistical significance of 
difference in nuclear localization of proteins examined in 
cells (by immunofluorescence) and in the percentage of 
cell growth/survival (by MTT assay) or apoptotic nuclei 
(by TUNEL assay) between two groups was analyzed with 
two-sided unpaired Student’s t tests when the variances 
were equal with Grahpad PRISM (Ver.6.07) statistical 
software (San Diego, CA) or Excel (Microsoft Office). All 
statistical tests were two-sided, and P values less than 0.05 
were considered statistically significant.
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